UNSPSC 51273910: Benzocaine/butamben/tetracaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class NT300. This VA Drug Class (NT300) classifies this compound as belonging to the group ANESTHETICS, MUCOSAL.

UNSPSC 51273910 Benzocaine/butamben/tetracaine, a Commodity code, sees little recent state and local procurement activity directly aligned with its nominal scope—the three most recent opportunities posted under this code involve naloxone and drug deactivation systems (Seminole County, Florida), a pharmacy benefit program RFI (Texas HHS), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota MMCAP), none of which center on the local anesthetic agents the code names. The mismatch suggests either misclassification in source systems or sporadic tagging against this code for related pharmaceutical procurement. When state and local bodies do solicit under related pharmaceutical codes, they typically procure through authorized wholesalers, require compliance with FDA manufacturing practices and Drug Supply Chain Security Act standards, and structure awards to support community health programs or multi-jurisdiction cooperative purchasing agreements.

Recent opportunities show activity concentrated in Florida and multi-state cooperative vehicles anchored in Minnesota, with secondary engagement from Texas HHS on prescription fulfillment innovation. Seminole County issued an IFB (IFB60459723LAS) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023 (note: date inconsistency in source), with quarterly delivery to the Seminole County Community Health Building and FEMA potential funding. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring vendor pricing flexibility, cGMP and DSCSA certification, and relationships with three authorized wholesalers. Texas HHS issued an exploratory RFI (HHS0017013) in April 2026 on direct-to-manufacturer prescription programs to inform future procurement strategy. No opportunities directly matching benzocaine or butamben procurement appear in recent postings.